Notably, the sensitivity and coverage enabled the illumination of heterogeneous cytoskeleton remodeling and cytokeratin signatures in patient‐derived cells resistant to third‐generation EGFR therapy, stratifying mixed‐lineage adenocarcinoma‐squamous cell carcinoma subtypes, and identifying alternative targeted therapy for late‐stage patients. Here, EGFR is linked to squamous cell carcinoma.